Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTA NASDAQ:IVVD NASDAQ:LIXT NASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$11.28-3.8%$13.54$6.43▼$17.15$341.09M0.97218,555 shs135,055 shsIVVDInvivyd$1.03-7.2%$1.36$0.48▼$3.07$327.01M0.633.17 million shs4.97 million shsLIXTLixte Biotechnology$7.00$4.43$0.64▼$7.50$86.68M1.27157,907 shs149,780 shsSOPHSOPHiA GENETICS$5.00+0.8%$4.94$2.59▼$5.70$339.69M0.9888,959 shs79,685 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals+4.36%-11.34%-18.99%-13.37%+64.98%IVVDInvivyd+0.91%-1.77%-20.14%-38.33%+14.54%LIXTLixte Biotechnology+4.32%+16.86%+55.90%+186.89%+403.60%SOPHSOPHiA GENETICS+3.77%-2.36%-2.17%+14.02%+65.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$11.28-3.8%$13.54$6.43▼$17.15$341.09M0.97218,555 shs135,055 shsIVVDInvivyd$1.03-7.2%$1.36$0.48▼$3.07$327.01M0.633.17 million shs4.97 million shsLIXTLixte Biotechnology$7.00$4.43$0.64▼$7.50$86.68M1.27157,907 shs149,780 shsSOPHSOPHiA GENETICS$5.00+0.8%$4.94$2.59▼$5.70$339.69M0.9888,959 shs79,685 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals+4.36%-11.34%-18.99%-13.37%+64.98%IVVDInvivyd+0.91%-1.77%-20.14%-38.33%+14.54%LIXTLixte Biotechnology+4.32%+16.86%+55.90%+186.89%+403.60%SOPHSOPHiA GENETICS+3.77%-2.36%-2.17%+14.02%+65.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.75Moderate Buy$20.2979.84% UpsideIVVDInvivyd 2.33Hold$8.00676.70% UpsideLIXTLixte Biotechnology 1.00SellN/AN/ASOPHSOPHiA GENETICS 2.33Hold$7.5050.00% UpsideCurrent Analyst Ratings BreakdownLatest LIXT, SOPH, ENTA, and IVVD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026IVVDInvivyd BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/26/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026IVVDInvivyd BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/14/2026IVVDInvivyd HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/12/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/6/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/29/2026IVVDInvivyd Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SOPHSOPHiA GENETICS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ENTAEnanta Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.003/26/2026ENTAEnanta Pharmaceuticals Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$65.32M5.02N/AN/A$3.03 per share3.72IVVDInvivyd$53.43M5.68N/AN/A$1.04 per share0.99LIXTLixte BiotechnologyN/AN/AN/AN/A$1.05 per shareN/ASOPHSOPHiA GENETICS$77.27M4.43N/AN/A$0.69 per share7.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$81.89M-$2.59N/AN/AN/A-89.56%-64.04%-20.22%8/10/2026 (Confirmed)IVVDInvivyd-$52.49M-$0.31N/AN/AN/A-138.90%-53.48%-41.56%8/13/2026 (Estimated)LIXTLixte Biotechnology-$6.01M-$1.13N/AN/AN/AN/A-134.91%-95.61%N/ASOPHSOPHiA GENETICS-$79M-$0.52N/AN/AN/A-44.48%-62.74%-21.85%8/4/2026 (Estimated)Latest LIXT, SOPH, ENTA, and IVVD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026IVVDInvivyd-$0.08-$0.13-$0.05-$0.13$18.04 million$13.74 million5/14/2026Q1 2026LIXTLixte BiotechnologyN/A-$0.18N/A-$0.18N/AN/A5/11/2026Q2 2026ENTAEnanta Pharmaceuticals-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million5/5/2026Q1 2026SOPHSOPHiA GENETICS-$0.2325-$0.27-$0.0375-$0.27$20.40 million$21.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A3.843.84IVVDInvivydN/A6.476.47LIXTLixte BiotechnologyN/A2.782.78SOPHSOPHiA GENETICS1.052.061.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%IVVDInvivyd70.36%LIXTLixte Biotechnology5.10%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals11.48%IVVDInvivyd12.25%LIXTLixte Biotechnology9.50%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16029.08 million25.74 millionOptionableIVVDInvivyd100294.61 million258.52 millionOptionableLIXTLixte Biotechnology412.38 million11.21 millionNot OptionableSOPHSOPHiA GENETICS52068.49 million65.14 millionNot OptionableLIXT, SOPH, ENTA, and IVVD HeadlinesRecent News About These CompaniesSophia Genetics and MSK join forces to develop precision oncology hubJune 5 at 9:37 AM | yahoo.comSOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer CenterJune 4 at 8:00 AM | prnewswire.comSOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $24,750.00 in StockJune 1, 2026 | marketbeat.comSOPHiA GENETICS Files Form 6-K and Publishes 2025 ESG Impact SummaryMay 19, 2026 | tipranks.comSynnovis and SOPHiA GENETICS partner to bring blood-based cancer testing to patients across UKMay 15, 2026 | pharmabiz.comPSynnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.May 13, 2026 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), SOPHiA GENETICS (SOPH) and Solventum Corporation (SOLV)May 9, 2026 | theglobeandmail.comSOPHiA GENETICS (NASDAQ:SOPH) Earns Buy Rating from BTIG ResearchMay 6, 2026 | marketbeat.comSOPHiA Genetics (SOPH) Q1 2026 Earnings TranscriptMay 5, 2026 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comBTIG Raises its Price Target on SOPHiA GENETICS (SOPH) to $8May 5, 2026 | finance.yahoo.comSOPHiA GENETICS Reports First Quarter 2026 ResultsMay 5, 2026 | prnewswire.comUncovering MTAP deletions in precision oncology researchApril 30, 2026 | labroots.comLHow The SOPHiA GENETICS (NasdaqGS:SOPH) Narrative Is Shifting With New Fair Value TargetsApril 26, 2026 | finance.yahoo.comSOPHiA GENETICS SAApril 23, 2026 | edition.cnn.comSOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026April 21, 2026 | prnewswire.comMount Sinai adopts AI platform to advance genomic testingApril 18, 2026 | beckershospitalreview.comBSOPHiA GENETICS (NASDAQ:SOPH) President Ross Muken Sells 2,800 SharesApril 17, 2026 | insidertrades.comMount Sinai uses AI to enhance the speed of genomic testingApril 16, 2026 | healthcareitnews.comHMount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026April 16, 2026 | prnewswire.comWell Daan Van Sells 2,400 Shares of SOPHiA GENETICS (NASDAQ:SOPH) StockApril 15, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked NameBy Leo Miller | June 1, 2026The Pentagon's AI Pivot Supercharges Defense StocksBy Jeffrey Neal Johnson | May 19, 2026Rocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?By Ryan Hasson | June 4, 2026Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record HighsBy Thomas Hughes | May 15, 2026LIXT, SOPH, ENTA, and IVVD Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$11.28 -0.45 (-3.84%) Closing price 04:00 PM EasternExtended Trading$11.28 0.00 (-0.04%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Invivyd NASDAQ:IVVD$1.03 -0.08 (-7.21%) Closing price 04:00 PM EasternExtended Trading$1.04 +0.01 (+0.97%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Lixte Biotechnology NASDAQ:LIXT$7.00 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$6.89 -0.11 (-1.57%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.SOPHiA GENETICS NASDAQ:SOPH$5.00 +0.04 (+0.81%) Closing price 04:00 PM EasternExtended Trading$5.00 +0.00 (+0.02%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
